Literature DB >> 15848660

Orthotopic liver transplantation for alagille syndrome.

G Maldini1, E Torri, A Lucianetti, M Guizzetti, D Pinelli, A Bertani, V Corno, M Giovanelli, M Zambelli, P Stroppa, D Alberti, G Torre, M Spada, B Gridelli, M Colledan.   

Abstract

Alagille syndrome (AS) is a dominantly inherited, multisystem disorder involving the liver, heart, eyes, face, and skeleton. From October 1997 through July 2004, 260 pediatric orthotopic liver transplantations (OLTx) were performed in 231 patients. This report describes 21 patients of median age 1.95 years (range, 0.7-16.7) who had alagille syndrome. We present the technical features of the OLTx, incidence and type of complications, medical conditions related to the syndrome, need for retransplantation, as well as patient and graft survival rates. A split liver technique was used in 16 patients (76%) who received a left lateral segment (LLS) graft whereas 7 patients (33%) received a whole liver. Only cadaveric donors were used. The major surgical complications requiring reintervention in 11 patients (52%) included biliary problems (19%) and vascular complications (17%). One case of hepatic artery thrombosis required retransplantation. Three recipients (14%) died. All other patients are alive with an actuarial survival rate of 90% at 1 year and 80% at 5 years. The actuarial graft survival rate is 85% at 1 year and 75% at 5 years. Patients with AS, despite the associated cardiovascular anomalies, can be treated successfully by a combined approach between cardiologist, radiologist, cardiothoracic, and liver transplant surgeons. With careful planning and operative management, the results are comparable with those obtained with other more common cholestatic diseases.

Entities:  

Mesh:

Year:  2005        PMID: 15848660     DOI: 10.1016/j.transproceed.2004.12.245

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.

Authors:  Kasper S Wang; Greg Tiao; Lee M Bass; Paula M Hertel; Douglas Mogul; Nanda Kerkar; Matthew Clifton; Colleen Azen; Laura Bull; Philip Rosenthal; Dylan Stewart; Riccardo Superina; Ronen Arnon; Molly Bozic; Mary L Brandt; Patrick A Dillon; Annie Fecteau; Kishore Iyer; Binita Kamath; Saul Karpen; Frederick Karrer; Kathleen M Loomes; Cara Mack; Peter Mattei; Alexander Miethke; Kyle Soltys; Yumirle P Turmelle; Karen West; Jessica Zagory; Cat Goodhue; Benjamin L Shneider
Journal:  Hepatology       Date:  2017-03-22       Impact factor: 17.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.